At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
Sitagliptindrug
Likely dose
Sitagliptin 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies
In Brief
A Phase 2 clinical trial evaluating Sitagliptin for Leukemia, Myeloid, Acute and 4 related conditions. Completed, enrolled 29 participants across 1 site.
Detailed Summary
The main purpose of this trial is to study whether the drug sitagliptin can be given safely to patients undergoing umbilical cord blood transplantation to speed up engraftment (recovery of blood counts after transplant).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia, Myelodysplasia, Leukemia, Myelogenous, Chronic, Lymphoma, Non-Hodgkin
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedMar 2009
Primary CompletionNov 2012
Study CompletionFeb 2015
TodayJul 2026
First PostedMar 17, 2009
Enrollment StartMar 1, 2009
Primary CompletionNov 1, 2012
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 17.3 years ago
Interventions
Sitagliptindrug
600 mg sitagliptin taken orally per the schedule listed in each of the three separate arms.